Lab Reagents
Human IgG antibody Laboratories manufactures the spike protein luciferase reagents distributed by Genprice. The Spike Protein Luciferase reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Spike products are available in stock. Specificity: Spike Category: Protein Group: Luciferase
Luciferase information
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
79942-1 |
BPS Bioscience |
100 µl |
EUR 875 |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
79942-2 |
BPS Bioscience |
500 µl x 2 |
EUR 4405 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
SARS Biotinylated Spike RBD Recombinant Protein |
10-212 |
ProSci |
0.1 mg |
EUR 752.1 |
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Sars-Cov, Spike (Middle) Recom Protein |
abx060656-1mg |
Abbexa |
1 mg |
EUR 2030.4 |
|
SARS Associated Spike Mosaic S Protein |
20-abx260156 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1646.40
|
|
|
Anti-MERSC-CoV Spike Protein antibody |
STJ140102 |
St John's Laboratory |
150 µg |
EUR 277.2 |
Description: Goat polyclonal to Spike protein of Middle East respiratory Syndrome coronavirus. Coronaviruses access host cells by membrane fusion, a process mediated by specific fusion or “spike” proteins on the virion, often activated by cellular proteases. |
Recombinant SARS Spike gp C Protein |
VAng-Lsx0072-inquire |
Creative Biolabs |
inquire |
Ask for price |
Description: SARS Spike glycoprotein C, recombinant protein from E. coli. |
SARS-CoV Spike Antibody |
3219-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3219-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
3221-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS (IN1) Spike Peptide |
3221P |
ProSci |
0.05 mg |
EUR 197.7 |
Description: (IN) SARS (IN1) Spike peptide |
SARS-CoV Spike Antibody |
3223-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Spike Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |